GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 18,006 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 18,006 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $78.18, for a total transaction of $1,407,709.08. Following the completion of the transaction, the chief executive officer now directly owns 53,140 shares of the company’s stock, valued at approximately $4,154,485.20. This represents a 25.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Katherine Stueland also recently made the following trade(s):

• On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total value of $805,951.75.
• On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total transaction of $279,590.57.
• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The stock was sold at an average price of $70.34, for a total transaction of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The stock was sold at an average price of $70.48, for a total value of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total value of $143,456.40.

GeneDx Stock Up 13.2 %

Shares of WGS stock traded up $10.47 during mid-day trading on Monday, reaching $89.61. 1,259,011 shares of the company’s stock traded hands, compared to its average volume of 808,279. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The company’s 50-day moving average price is $76.28 and its 200-day moving average price is $51.22. The company has a market cap of $2.46 billion, a P/E ratio of -28.81 and a beta of 2.03. GeneDx Holdings Corp. has a 12 month low of $2.80 and a 12 month high of $89.66.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.25. The firm had revenue of $76.90 million for the quarter, compared to analysts’ expectations of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business’s revenue for the quarter was up 44.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.82) EPS. On average, equities analysts expect that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GeneDx

Several large investors have recently modified their holdings of the stock. Acadian Asset Management LLC bought a new stake in GeneDx during the 2nd quarter valued at about $34,000. CWM LLC purchased a new position in GeneDx in the 3rd quarter worth approximately $89,000. Verition Fund Management LLC lifted its position in GeneDx by 12.9% in the 3rd quarter. Verition Fund Management LLC now owns 25,845 shares of the company’s stock valued at $1,097,000 after acquiring an additional 2,945 shares in the last quarter. American Century Companies Inc. boosted its stake in GeneDx by 36.1% during the 2nd quarter. American Century Companies Inc. now owns 17,258 shares of the company’s stock valued at $451,000 after purchasing an additional 4,573 shares during the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of GeneDx in the 3rd quarter worth $198,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on WGS shares. Wells Fargo & Company upped their price target on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. Craig Hallum raised their price target on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Finally, The Goldman Sachs Group upped their price objective on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $59.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.